Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

101.65USD
4 Mar 2015
Change (% chg)

$-0.69 (-0.67%)
Prev Close
$102.34
Open
$102.04
Day's High
$102.05
Day's Low
$101.17
Volume
2,899,610
Avg. Vol
2,681,974
52-wk High
$109.49
52-wk Low
$92.26

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being.... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $284,555.19
Shares Outstanding(Mil.): 2,780.49
Dividend: 0.70
Yield (%): 2.74

Financials

  JNJ.N Industry Sector
P/E (TTM): 17.95 39.75 40.37
EPS (TTM): 5.70 -- --
ROI: 15.32 16.86 16.19
ROE: 22.70 17.37 17.14
Search Stocks

J&J nearing deal to buy cancer drug maker Pharmacyclics: FT

- Johnson & Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days, the Financial Times reported, citing sources.

5:01am IST

J&J nearing deal to buy cancer drug maker Pharmacyclics - FT

March 4 - Johnson & Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days, the Financial Times reported, citing sources.

4:57am IST

BRIEF-J&J nearing deal to buy Pharmacyclics - FT

* Johnson & Johnson nearing deal to buy Pharmacyclics Inc - Financial Times Source text (http://on.ft.com/1EhbLrQ)

3:13am IST

Deals of the day- Mergers and acquisitions

March 2 - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:

03 Mar 2015

Cardinal to buy J&J vascular technology unit Cordis for $1.9 billion

NEW YORK - U.S. pharmaceutical and medical equipment maker Johnson & Johnson said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health for $1.9 billion, completing its exit from the cardiovascular stent business.

02 Mar 2015

UPDATE 3-Cardinal to buy J&J vascular technology unit Cordis for $1.9 bln

NEW YORK, March 2 - U.S. pharmaceutical and medical equipment maker Johnson & Johnson said on Monday it agreed to sell its Cordis vascular technology unit to Cardinal Health for $1.9 billion, completing its exit from the cardiovascular stent business.

02 Mar 2015

Cardinal to buy J&J vascular technology unit Cordis for $1.9 bln

NEW YORK, March 2 - Cardinal Health said on Monday that it would buy Johnson & Johnson's Cordis vascular technology unit for $1.9 billion and that the acquisition would boost 2017 earnings by 20 cents per share.

02 Mar 2015

South Carolina court orders Johnson & Johnson to pay $136 million in Risperdal case

- South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.

26 Feb 2015

South Carolina court orders J&J to pay $136 mln in Risperdal case

Feb 26 - South Carolina's Supreme Court ordered Johnson & Johnson to pay a penalty of $136 million, upholding a jury's finding that the drugmaker's Janssen unit had improperly marketed its anti-psychotic drug Risperdal and concealed its risks.

26 Feb 2015

Pharmacyclics mulls sale; J&J, Novartis interested: Bloomberg

- Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson & Johnson and Novartis AG , Bloomberg reported.

26 Feb 2015

Earnings vs. Estimates

Search Stocks